Close
The iEuroEwing trial is international and is open to recruitment.
The CI for the iEuroEwing trial is Professor Uta Dirksen, University Hospital Essen (Germany).
The trial is international and is open to recruitment.
Main objectives
iEuroEwing-SR part: The main goal is to conduct a randomised trial part. This will examine, whether the addition of a maintenance treatment using VinoCyc to nine cycles of VDC/IE improves EFS in patients with primary disease, aiming at a 10% increase of a 3-year EFS compared to the standard VDC/IE treatment.
iEuroEwing-SR part RT: The main goal is to show in a randomised setting, that a higher RT dose is not inferior regarding an acute skin toxicity CTCAE grade≥3 under RT. The non-inferiority margin for the risk difference is 8% between the combined lower dose and combined higher dose RT arms.
iEuroEwing-HR part: The main goal is to conduct a randomised trial part. This will examine, whether the addition of a maintenance treatment using VinoCyc to nine cycles of VDC/IE improves EFS in patients with primary disseminated
disease, aiming at a 17% increase of 2-year EFS compared to the standard VDC/IE treatment.
More information
More information is available at the EU Clinical Trials Register.